Document is current
Any future updates will be listed below
-
Authors
Norman, Maia http://orcid.org/0000-0002-9654-4904
Gilboa, Tal
Ogata, Alana F.
Maley, Adam M. http://orcid.org/0000-0003-1851-984X
Cohen, Limor http://orcid.org/0000-0003-1448-0925
Busch, Evan L. http://orcid.org/0000-0001-6829-6846
Lazarovits, Roey
Mao, Chih-Ping
Cai, Yongfei http://orcid.org/0000-0002-3628-3802
Zhang, Jun
Feldman, Jared E.
Hauser, Blake M. http://orcid.org/0000-0002-0100-1684
Caradonna, Timothy M.
Chen, Bing http://orcid.org/0000-0002-8625-1657
Schmidt, Aaron G.
Alter, Galit http://orcid.org/0000-0002-7680-9215
Charles, Richelle C. http://orcid.org/0000-0002-8881-1849
Ryan, Edward T.
Walt, David R. http://orcid.org/0000-0002-5524-7348
-
Funding
Funding for this research was provided by:
Massachusetts Consortium for Pathogen Readiness
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (T32 AI007245, R01AI146779)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007753, T32GM007753)
US Centers for Disease Control and Prevention
- License Information
-
More Information
Article History
Received: 12 June 2020
Accepted: 17 August 2020
First Online: 18 September 2020
Competing interests
: D.R.W. has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the Simoa technology and a founder of the company and also serves on its Board of Directors. D.R.W.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their policies on competing interests. The assays in this publication have been licensed by Brigham and Women’s Hospital to Quanterix Corporation. M.N., T.G., A.F.O., A.M.M. and D.R.W. have filed intellectual property on the technology described in this manuscript. L.C., E.L.B., R.L., C.-P.M., Y.C., J.Z., J.E.F., B.M.H., T.M.C., B.C., A.G.S., G.A., R.C.C. and E.T.R. declare no competing interests.
Free to read: This content has been made available to all.
